After 2 Patient Deaths FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045

After 2 Patient Deaths, FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045

Xencor acknowledged today that the FDA has placed the company’s Phase I trial of its CD123 x CD3 bispecific antibody XmAb®14045 on a partial clinical hold following the deaths of two patients linked to the blood cancer candidate. Xencor said one patient experienced cytokine release syndrome (CRS) after their first dose, “the treatment of which […]

More From BioPortfolio on "After 2 Patient Deaths, FDA Imposes Partial Clinical Hold on Trial of Xencor Blood Cancer Antibody XmAb14045"